Clinical trial · Interventional
Radiofrequency Ablation of Malignant Pulmonary Nodules
Efficacy and Safety of Radiofrequency Ablation of Malignant Pulmonary Nodules
NCT02629978CI-TRIAL-00020206unknownN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The objective of this study is to evaluate the outcomes of radiofrequency ablation in the treatment of patients with malignant pulmonary nodules（not exceed 3cm ）who are not suitable candidates for or refuse surgical resection.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| CT-guided percutaneous radiofrequency ablation | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- radiofrequency ablation
- description
- In this group, patients willingly receive CT-guided percutaneous radiofrequency ablation procedures are selected according to the inclusion criteria as follows. After a series of preoperative evaluation and preoperative preparation，the procedures will be performed under the CT guidance. CT/MRI scans will be ordered after 24-48 hours to see if there are complications (such as haemorrhage, pneumothorax and pleural effusion). Regularly follow-up will be carried out for several years after RFA to assess the effectiveness and safety of RFA integratedly.
- interventionNames
- Procedure: CT-guided percutaneous radiofrequency ablation
Primary outcomes (2)
- measure
- 1- , 3- and 5-year survival rates
- timeFrame
- up to 5 years after the procedures
- measure
- complication rate
- timeFrame
- During the procedure or up to 5 years after the procedures
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: 1. Histologically confirmed malignant pulmonary nodules. 2. Patients refuse or are not suitable for surgical resections. 3. 1-3 pulmonary nodules , with a maximum tumor diameter ≦30 mm. 4. Minimum distance of nodules are at least 10 mm apart from the surrounding tissues as big trachea, primary bronchi, esophagus, great vessels，heart and pleura. Exclusion Criteria: 1. Patients who has uncorrectable coagulation disorders, severe heart or pulmonary failure, or uncontrolled infections. 2. With extensive extrapulmonary or intrapulmonary metastasis. 3. Have taken anticoagulant as aspirin in one week. 4. Target nodules nearby pleura or other important hilum and mediastinum structures. 5. With metal implants are adjacent to the target tissues which will be covered with ablation area.
References
Publications (0)
Data not yet available
No reference posted for this study.